EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1‐Mediated AMPK Signalling

Fuyan Hong, Zhenzhen Fang, Gang Shen, Yan Wang, Yunhua Li, Youbin Zhong, Junze Dai, Chengwei Zhang, Jing Zhang, Wencan Chen, Weiwei Qi, Xia Yang und 2 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Fuyan Hong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Receptors, Adiponectin, Serpins, Exercise Tolerance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Natural Science Fund, The Open Project Program of Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pathological intramuscular lipid deposition (myosteatosis) and exercise intolerance are hallmarks of metabolic disorders, including diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD), yet their underlying mechanisms remain unclear. Our previous work has confirmed that hypertriglyceridemia‐driven kallistatin (KAL) elevation is present in the peripheral blood of patients with MASLD and diabetes and is a causative factor in hepatic steatosis and MASH pathogenesis. Here, we aim to evaluate this elevated KAL on myosteatosis and exercise function.

Methods

We first established rat models of myosteatosis via a high‐fat diet or high‐fructose water intake and measured serum KAL levels by immunoblotting. KAL transgenic (KAL‐TG) mice were generated and subjected to longitudinal analyses, including Oil Red O staining for lipid deposition, exercise tolerance tests, indirect calorimetry for energy expenditure, mitochondrial DNA copy number quantification, ATP measurement, immunoblotting and quantitative PCR. For mechanistic analyses, mouse C2C12 myotubes were treated with recombinant KAL or KAL adenovirus, with or without co‐treatment with AICAR, AdipoRon or AdipoR1 siRNA. Additionally, we evaluated the potential ameliorative effects of KAL knockout and target agonists on myosteatosis.

Results

Serum KAL levels were significantly elevated in rat models of myosteatosis. Conversely, genetic ablation of KAL ameliorated diet‐induced muscle lipid deposition. KAL‐TG mice developed myosteatosis (muscle TG [μmol/g]: WT: 54.26 ± 14.56 [95% CI: 38.99–69.54]; KAL‐TG: 85.13 ± 11.53 [95% CI: 73.03–97.24], p < 0.01) and exhibited exercise intolerance ( p < 0.05 for all) from 6 months of age. Mechanistically, KAL bound to sarcolemmal adiponectin receptor 1 (AdipoR1), suppressing AMPK activity. This led to reduced phosphorylation of acetyl‐CoA carboxylase (ACC) ( p < 0.05), enhancing lipogenesis and downregulated the PGC‐1α/NRF1 axis ( p < 0.05), impairing mitochondrial biogenesis and reducing ATP production ( p < 0.05). Pharmacological activation of AdipoR1 (AdipoRon) and fenofibrate attenuated myosteatosis and restored exercise capacity in KAL‐TG mice ( p < 0.05).

Conclusions

Abnormal elevation of KAL drives metabolic myopathy and exercise intolerance by antagonizing the AdipoR1‐AMPK axis. Our findings offer dual strategies: repurposing AdipoR1 agonists (e.g., AdipoRon) or reducing circulating KAL (e.g., via genetic ablation or triglyceride‐lowering agents such as fenofibrate), both applicable to diabetes/MASLD‐related metabolic myopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP-Activated Protein KinasesReceptors, AdiponectinSerpinsExercise ToleranceAnimalsMiceSignal TransductionRatsMice, TransgenicMaleHumansDisease Models, AnimalMuscle, Skeletal

Stichwörter der Autor:innen

AMPKAdipoR1kallistatinlipogenesismitochondrial biogenesismyosteatosis

Substanzen

kallistatinAMP-Activated Protein KinasesReceptors, AdiponectinSerpins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
  • Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Laboratory Medicine, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Engineering and Technology Research Center for Gene Manipulation and Bio-macromolecular Products, Sun Yat-Sen University, Guangzhou, China.
  • China Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, Guangdong, China.

ORCID-Profile: Ti Zhou

Förderung

  • National Natural Science Foundation of China
  • Guangdong Natural Science Fund
  • The Open Project Program of Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University

Zitieren

APA

Hong, F., Fang, Z., Shen, G., Wang, Y., Li, Y., Zhong, Y., Dai, J., Zhang, C., Zhang, J., Chen, W., Qi, W., Yang, X., Gao, G., & Zhou, T. (2026). Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1‐Mediated AMPK Signalling. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70261

Vancouver

Hong F, Fang Z, Shen G, Wang Y, Li Y, Zhong Y, et al. Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1‐Mediated AMPK Signalling. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70261

BibTeX
@article{Hong2026,
  author = {Hong, Fuyan and Fang, Zhenzhen and Shen, Gang and Wang, Yan and Li, Yunhua and Zhong, Youbin and Dai, Junze and Zhang, Chengwei and Zhang, Jing and Chen, Wencan and Qi, Weiwei and Yang, Xia and Gao, Guoquan and Zhou, Ti},
  title = {Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1‐Mediated AMPK Signalling},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70261}
}
Kostenlos starten →